Comparative Risk of Harm Associated With the Use of Targeted Immunomodulators: A Systematic Review

ConclusionImportant differences were noted in the safety profile of TIMs in RA, generally favoring abatacept, adalimumab, and etanercept over infliximab. Head‐to‐head comparative evidence for other TIMs and non‐RA populations was insufficient to draw conclusions for most of the safety outcomes.

Source: Arthritis Care and Research - July 21, 2016 Category: Rheumatology Authors: Rishi J. Desai, Kylie J. Thaler, Peter Mahlknecht, Gerald Gartlehner, Marian S. McDonagh, Bita Mesgarpour, Alireza Mazinanian, Anna Glechner, Chandrasekar Gopalakrishnan, Richard A. Hansen Tags: Rheumatoid Arthritis Source Type: research